GlassScriptPhysician profile
Gregory B Guinoo
NPI 1891062188
$1,497.76
in general payments reported to CMS, 2019-2025
19 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $415 · 2022: $174 · 2023: $469 · 2024: $140 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $244.02 | 2021-2023 | Jakafi |
| Janssen Scientific Affairs, LLC | $145.70 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| Abbvie INC. | $130.39 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $127.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $114.64 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Celgene Corporation | $101.44 | 2021-2023 | Onureg, Reblozyl |
| Kite Pharma, INC. | $96.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.94 | 2022-2023 | Livtencity |
| Pharmacyclics LLC, An Abbvie Company | $79.86 | 2021-2023 | Imbruvica |
| Autolus INC | $64.86 | 2025 | |
| Genentech USA, INC. | $53.75 | 2024-2025 | Venclexta, Lunsumio, Columvi |
| Legend Biotech USA INC. | $44.07 | 2023-2025 | Carvykti |
| Sanofi-Aventis U.S. LLC | $37.10 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $35.54 | 2022 | |
| Genmab U.S., INC. | $31.54 | 2024 | Epkinly |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $29.14 | 2023-2024 | Tecvayli, Darzalex, Talvey |
| Secura Bio, INC. | $24.41 | 2025 | Copiktra |
| Karyopharm Therapeutics INC. | $23.58 | 2023 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $22.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Guinoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.